Bristol Myers Squibb states that a pre/postoperative regimen of Opdivo (nivolumab) and chemotherapy significantly improves survival in operable non-small cell lung cancer patients.

This article summarized the latest R&D progress of Streptozocin, the Mechanism of Action for Streptozocin, and the drug target R&D trends for Streptozocin.

ICF stands for Informed Consent Form, which is a document proof that each participant voluntarily participates in a certain experiment.

This article summarized the latest R&D progress of Stiripentol, the Mechanism of Action for Stiripentol, and the drug target R&D trends for Stiripentol.

Inmagene has established Celexor Bio, which is premised on its anti-ILT7 mAb that demonstrates improved pDC reduction capabilities.

This article summarized the latest R&D progress of Sintilimab, the Mechanism of Action for Sintilimab, and the drug target R&D trends for Sintilimab.

A protocol outlines the experiment's context, theory, and intent, its design, methodology, and structure including statistical considerations, and the conditions for execution and completion.

This article summarized the latest R&D progress of Sargramostim, the Mechanism of Action for Sargramostim, and the drug target R&D trends for Sargramostim.

The Phase 3 TROPION-Breast01 trial showed that Datopotamab Deruxtecan significantly improved progression-free survival for patients with HR positive, HER2 low or negative breast cancer.

This article summarized the latest R&D progress of Rocuronium Bromide, the Mechanism of Action for Rocuronium Bromide, and the drug target R&D trends for Rocuronium Bromide.

DSMB stands for Data Safety and Monitoring Board, an independent expert group established to safeguard the rights and needs of infants and young children participating in Phase III clinical trials.

This article summarized the latest R&D progress of Ripretinib, the Mechanism of Action for Ripretinib, and the drug target R&D trends for Ripretinib.